A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies

[1]  C. Kang,et al.  Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma. , 2013, Lung cancer.

[2]  Lu Wang,et al.  Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. , 2013, Cancer discovery.

[3]  P. Bunn,et al.  RET rearrangements detected by FISH in "pan-negative" lung adenocarcinoma. , 2013 .

[4]  S. Aebi,et al.  A patient with lung adenocarcinoma and RET fusion treated with vandetanib. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  Caicun Zhou,et al.  KIF5B‐RET fusions in Chinese patients with non–small cell lung cancer , 2013, Cancer.

[6]  J. Ji,et al.  FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547 , 2013, Clinical Cancer Research.

[7]  P. Jänne,et al.  New targetable oncogenes in non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Ji,et al.  RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Hiroyuki Aburatani,et al.  Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  Tatsuo Ito,et al.  Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions , 2012, Clinical Cancer Research.

[11]  H. Sasaki,et al.  KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. , 2012, Oncology reports.

[12]  H. Sasaki,et al.  RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer , 2012, Cancer medicine.

[13]  Identification of RET gene fusion by exon array analyses in “pan-negative” lung cancer from never smokers , 2012, Cell Research.

[14]  Doron Lipson,et al.  Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.

[15]  Seungbok Lee,et al.  A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. , 2012, Genome research.

[16]  Yasushi Totoki,et al.  KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.

[17]  Yuki Togashi,et al.  RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.

[18]  A. Tsao.  Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR) , 2012 .

[19]  A. Wolff,et al.  A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixed-dose capecitabine in metastatic breast cancer (MBC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Michael Thomas,et al.  Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Chih-Hsin Yang,et al.  Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Yan Sun,et al.  Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. , 2010, The Lancet. Oncology.

[23]  J. Vansteenkiste,et al.  Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Pinchera,et al.  Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.

[25]  C. Hedinger,et al.  Papillary thyroid carcinomas , 1982, Virchows Archiv A.

[26]  G. Fontanini,et al.  ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. , 2002, Cancer research.

[27]  B. Curry,et al.  ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. , 2002, Cancer research.

[28]  P. Goodfellow,et al.  Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Goodfellow,et al.  Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. , 1993, Human molecular genetics.

[30]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[31]  M. Borrello,et al.  Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas. , 1992, Oncogene.